RGNX · Regenxbio Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.39M | - | $29.73M | $21.36M | $89.01M | - | $24.20M | $22.30M | $15.62M | - |
| Cost of Revenue | - | - | - | - | - | - | $12.39M | $10.58M | $4.28M | - |
| Gross Profit | - | - | - | - | - | - | $11.81M | $11.72M | $11.34M | - |
| R&D | $57.34M | - | $56.10M | $59.50M | $53.09M | - | $54.43M | $48.87M | $54.84M | - |
| SG&A | $21.31M | - | $20.25M | $19.88M | $20.35M | - | $19.42M | $18.86M | $18.29M | - |
| Total Operating Expenses | $89.75M | - | $82.14M | $84.64M | $76.89M | - | $86.28M | $78.33M | $79.48M | - |
| D&A | $3.86M | - | - | - | $3.96M | - | - | - | $4.18M | - |
| Operating Income | ($83.36M) | - | ($52.41M) | ($63.28M) | $12.13M | - | ($62.08M) | ($56.04M) | ($63.86M) | - |
| Interest Expense | $8.71M | - | $13.17M | $449.0K | $1.97M | - | $820.0K | $449.0K | $1.97M | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($90.05M) | - | ($61.94M) | ($70.87M) | $6.08M | - | ($59.60M) | ($52.99M) | ($63.33M) | - |
| EPS - Basic | ($1.72) | - | ($1.20) | ($1.38) | $0.12 | - | ($1.17) | ($1.05) | ($1.38) | - |
| EPS - Diluted | ($1.72) | - | ($1.20) | ($1.38) | $0.12 | - | ($1.17) | ($1.05) | ($1.38) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.23M | $34.47M | $58.80M | $79.56M | $130.10M | $57.53M | $56.62M | $57.77M | $112.97M | $34.52M |
| Accounts Receivable | $10.04M | $26.38M | $25.35M | $20.20M | $18.19M | $20.47M | $23.60M | $22.81M | $15.83M | $24.79M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $21.21M | $21.36M | $22.27M | $21.66M | $19.04M | $22.80M | $19.52M | $16.36M | $31.36M | $22.79M |
| Current Assets | $186.52M | $281.28M | $331.97M | $373.75M | $313.24M | $278.00M | $313.40M | $346.68M | $395.42M | $334.97M |
| Total Assets | $341.89M | $453.03M | $525.20M | $581.03M | $490.93M | $465.99M | $519.11M | $569.38M | $629.22M | $573.97M |
| Current Liabilities | $71.11M | $118.09M | $124.57M | $119.54M | $106.73M | $103.19M | $102.72M | $98.27M | $110.18M | $130.27M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $320.81M | $350.30M | $363.75M | $367.35M | $216.73M | $206.34M | $217.70M | $221.11M | $238.55M | $262.23M |
| Stockholders' Equity | $21.08M | $102.73M | $161.45M | $213.68M | $274.20M | $259.65M | $301.42M | $348.27M | $390.67M | $311.74M |
| Retained Earnings | ($1.22B) | ($1.13B) | ($1.06B) | ($996.94M) | ($926.07M) | ($932.15M) | ($880.96M) | ($821.37M) | ($768.38M) | ($705.05M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($76.19M) | - | - | - | $33.63M | - | - | - | ($55.45M) | - |
| Investing Cash Flow | $70.59M | - | - | - | $44.74M | - | - | - | $13.18M | - |
| Financing Cash Flow | ($13.64M) | - | - | - | ($5.79M) | - | - | - | $120.72M | - |
| CapEx | $1.24M | - | - | - | $1.02M | - | - | - | $557.0K | - |
| Free Cash Flow | ($77.42M) | - | - | - | $32.60M | - | - | - | ($56.01M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | 48.8% | 52.5% | 72.6% | - |
| Operating margin | -1304.0% | - | -176.3% | -296.3% | 13.6% | - | -256.6% | -251.3% | -408.8% | - |
| EBITDA margin | -1243.6% | - | - | - | 18.1% | - | - | - | -382.0% | - |
| Net margin | -1408.6% | - | -208.3% | -331.8% | 6.8% | - | -246.3% | -237.7% | -405.4% | - |
| Free cash flow margin | -1211.0% | - | - | - | 36.6% | - | - | - | -358.5% | - |
| FCF / Net income | 0.86 | - | - | - | 5.36 | - | - | - | 0.88 | - |
| R&D / Revenue | 896.9% | - | 188.7% | 278.6% | 59.6% | - | 224.9% | 219.2% | 351.1% | - |
| SG&A / Revenue | 333.3% | - | 68.1% | 93.1% | 22.9% | - | 80.3% | 84.6% | 117.1% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -26.3% | - | -11.8% | -12.2% | 1.2% | - | -11.5% | -9.3% | -10.1% | - |
| Return on equity | -427.1% | - | -38.4% | -33.2% | 2.2% | - | -19.8% | -15.2% | -16.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.62 | 2.38 | 2.66 | 3.13 | 2.93 | 2.69 | 3.05 | 3.53 | 3.59 | 2.57 |
| Quick ratio | 2.62 | 2.38 | 2.66 | 3.13 | 2.93 | 2.69 | 3.05 | 3.53 | 3.59 | 2.57 |
| Cash ratio | 0.21 | 0.29 | 0.47 | 0.67 | 1.22 | 0.56 | 0.55 | 0.59 | 1.03 | 0.26 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -9.6x | - | -4.0x | -140.9x | 6.1x | - | -75.7x | -124.8x | -32.4x | - |
| Equity multiplier | 16.22 | 4.41 | 3.25 | 2.72 | 1.79 | 1.79 | 1.72 | 1.63 | 1.61 | 1.84 |
| Liabilities / Assets | 0.94 | 0.77 | 0.69 | 0.63 | 0.44 | 0.44 | 0.42 | 0.39 | 0.38 | 0.46 |
| Efficiency | ||||||||||
| Asset turnover | 0.02 | - | 0.06 | 0.04 | 0.18 | - | 0.05 | 0.04 | 0.02 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 573d | - | 311d | 345d | 75d | - | 356d | 373d | 370d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | 575d | 565d | 2672d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | 59.6x | - | - | - | - | - |
| P / B | 20.8x | - | 3.1x | 2.0x | 1.3x | - | 1.8x | 1.7x | 2.5x | - |
| P / S | 68.7x | - | 16.8x | 19.8x | 4.1x | - | 22.0x | 26.6x | 61.7x | - |
| EV / EBITDA | - | - | - | - | 14.8x | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -92.8% | - | 22.9% | -4.2% | 469.8% | - | -16.3% | 11.6% | -18.4% | - |
| Revenue CAGR (3y) | -30.6% | - | 3.9% | -13.2% | 58.8% | - | -7.7% | 0.4% | -6.1% | - |
| Revenue CAGR (5y) | -19.5% | - | -21.4% | 5.2% | 38.2% | - | 10.5% | 23.1% | 77.6% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | -28.5% | 11.6% | -24.5% | - |
| Operating income growth (YoY) | - | - | 15.6% | -12.9% | - | - | 4.4% | 23.4% | 3.5% | - |
| Net income growth (YoY) | - | - | -3.9% | -33.7% | - | - | 3.7% | 26.5% | 5.0% | - |
| EPS growth (YoY) | - | - | -2.6% | -31.4% | - | - | 17.0% | 36.7% | 9.8% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 34.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -92.3% | -60.4% | -46.4% | -38.6% | -29.8% | -16.7% | -17.0% | -14.2% | -16.0% | -39.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$170.44M totalLicense And Service$156.27M · 91.7%
Service$14.17M · 8.3%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing REGENXBIO Inc. against the 5 most active filers in the same SIC group.